Drug distributors went three-for-three, with Cardinal Health putting up the last fall-quarter beat on Thursday, following the examples set by McKesson and Cencora. The post Drug Wholesalers Go Three-For-Three In Earnings Beats, But Only Two Stocks Pop appeared first on…
COR Cencora, Inc.
XNYS
335.74
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
COR
$335.74
—
Key stats
$335.74
- 52-Week Range
- $244.82 – $377.54
- YTD
- -0.92%
- IV Rank (30D)
- 41.01
- Straddle Price
- $27.15
- P/C Vol Ratio
- 0.18
- Market Cap
- $64.8B
- Open
- $333.61
- Day Range
- $332.67 – $338.54
- Volume
- 555,874
- Prev Close
- $339.68
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.95% |
| Beta vs SPY | 0.39 |
| Cost of Equity (CAPM) | 6.89% (VRP-adj) |
| WACC | 6.63% |
| Volatility Risk Premium | +23.0pp (IV − HV30) |
| Effective Tax Rate | 26.8% |
| Rev. Growth (YoY, DCF input) | +1.2% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.01 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $4.1B |
| Return on Equity (TTM) | 86.0% |
| Book / Price | 4.9% |
| Gross Margin (TTM) | 4.0% |
| FCF Margin (TTM) | 1.2% |
| Debt / Equity | 3.53 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| Market-Implied Growth | -3.9% (reverse-DCF on current price) |
| SMA 50 | $324.87 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $335.19 |
| Bollinger Width / SMA20 | 2.7% (drives anchor stability) |
| Net Debt | $8.6B |
| Market Cap | $66B |
Peers used for multiples: AAPL, ABBV, AMZN, JNJ, LLY, MCK, MRK, MSFT
Blended Fair Value
$1081.77
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $443.23 | 19% | |
| DDM (Gordon) | $54.71 | 0% | |
| Peer P/E | $543.77 | 9% | median 39.9× · 8 peers |
| Peer EV/EBITDA | $552.71 | 9% | median 20.5× · 8 peers |
| Peer P/B | $146.37 | 2% | median 8.8× · 6 peers |
| Peer P/S | $12603.91 | 6% | median 7.3× · 8 peers |
| Market Anchor (SMA50) | $324.87 | 38% | stability 100% (BB-width) |
| Options Expected (B-L 30d) | $341.85 | 19% | 21 strikes · skew +0.87 |
As of 2026-11-06 · updated
Related
About
- Industry (SIC)
- WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES (5122) · industry map
- Exchange
- XNYS
- Market Cap
- $64.8B
- Employees
- 51,000
- List Date
- 1995-04-04
- CIK
- 0001140859
- Headquarters
- Conshohocken, PA
- Homepage
- https://www.cencora.com
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices and global specialty drug logistics (World Courier). Cencora expanded its international presence in 2021 by purchasing Alliance Healthca…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|
| Jan | 10.67% | -- | 11.58% | 13.11% | 6.01% | 10.34% |
| Feb | -12.38% | -- | -0.56% | -0.35% | 2.36% | -2.73% |
| Mar | 1.49% | -- | 2.51% | 8.89% | -15.70% | -0.70% |
| Apr | -1.81% | -- | -1.63% | 5.50% | -3.04% | -0.24% |
| May | 0.21% | -- | -1.15% | 0.28% | -11.39% | -3.01% |
| Jun | 10.68% | -- | -2.26% | 2.66% | 6.91% | 4.50% |
| Jul | 5.05% | -- | 6.42% | -3.13% | 8.13% | 4.12% |
| Aug | 6.90% | -1.63% | -2.00% | 1.13% | 4.94% | 1.87% |
| Sep | -8.71% | 2.86% | -7.65% | 6.00% | -9.28% | -3.36% |
| Oct | 1.71% | 3.39% | 1.72% | 8.35% | 6.80% | 4.39% |
| Nov | 16.01% | 8.62% | 7.38% | 8.21% | -0.49%* | 7.95% |
| Dec | -0.26% | 0.63% | -10.08% | -6.21% | -- | -3.98% |
| Total | 29.31% | 14.35% | 2.26% | 52.22% | -8.08% | 18.01% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $335.80
SMA 50: $325.16
SMA 200: $316.80
Current: $336.06
EMA 12: $336.66
EMA 26: $331.97
MACD: 4.6912 | Signal: 0.2458
BULLISH
ADX (14): 22.36
WEAK TREND
+DI: 33.76
−DI: 16.52
Momentum Oscillators
RSI (14): 53.46
NEUTRAL
Stoch %K: 58.85
Stoch %D: 71.44
Williams %R: -63.55
Volume & Volatility
BB Upper: $350.15
BB Lower: $321.45
NEUTRAL
OBV: 23,863,716
Vol SMA 20: 1,364,657
Vol ROC: -52.47%
ATR: $9.28
True Range: $7.01
HV 20: 27.9%
HV 30: 26.5%
HV 60: 24.0%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-07T00:00:00 – 2026-11-05T00:00:00
AI Analysis
LLM Stock Analysis Report - COR
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers:
- Technical indicators suggest a neutral trend with momentum building
- Recent news headlines have been mostly neutral, with some negative sentiment
Primary Risks:
- High beta (-0.21) indicates the stock moves opposite to the market
- Volatility is relatively high (0.32), increasing risk
Investment Thesis: COR's current price ($313.01) is near its 50-day SMA ($297.15), indicating a potential consolidation phase. The bullish MACD signal and rising momentum oscillators suggest a potential uptrend, but the neutral RSI reading suggests caution.
Recent News Sentiment Impact: The recent negative news headline on Cencora's fraud investigation has likely had a negative impact on sentiment, contributing to the current neutral assessment.
Technical Analysis
Trend Direction: Medium-term (1-3 months) uptrend
Support/Resistance Levels: Key levels include:
- Upper Bollinger Band: $327.91
- Middle Bollinger Band: $312.42
- Lower Bollinger Band: $296.94
- 20-day SMA: $312.42
Momentum Signals:
- RSI interpretation: Neutral (52.84)
- MACD signal: Bullish (5.35 / Signal: -0.92 / Histogram: 6.27)
- Bollinger Bands position: Squeeze (neutral)
Volume Analysis: Volume has been trending upward, with a recent surge in volume (1393320.85). The OBV indicator is rising, suggesting buying pressure.
News & Sentiment Analysis
Recent Headlines Summary: Mostly neutral headlines, with some negative sentiment from the Cencora fraud investigation.
Sentiment Assessment: Aggregate news sentiment is NEUTRAL, with some recent negative news contributing to caution.
Catalyst Identification: No imminent catalysts are apparent, but earnings data would be a significant event risk.
Market Narrative: The technical signals and neutral sentiment suggest a consolidation phase, while the recent negative news headline has contributed to caution.
Risk & Volatility Assessment
Beta Interpretation: High beta (-0.21) indicates the stock moves opposite to the market, increasing risk.
Volatility Regime: Current volatility is relatively high (0.32), with a high IV premium (91.8%) suggesting implied volatility is richer than realized.
Options Market Signals:
- IV rank: Medium (42.7%)
- Put/call volume ratio: Neutral (0.88)
- Open interest: 2,739 calls vs 1,350 puts
Downside Protection: Support levels include the lower Bollinger Band ($296.94) and the 50-day SMA ($297.15).
Market Context & Positioning
Sector Performance: COR is relatively weak compared to its sector peers.
Institutional Activity: Institutional interest is moderate, with some buying pressure visible in the options market.
Correlation Analysis: The stock has a negative correlation (-0.09) with the market, indicating it moves opposite to the broader market.
Relative Valuation: COR is trading near its 50-day SMA, which could be seen as relatively cheap compared to its historical volatility.
Key Levels & Action Items
Critical Price Levels:
- Upper Bollinger Band: $327.91
- Middle Bollinger Band: $312.42
- Lower Bollinger Band: $296.94
- 20-day SMA: $312.42
Breakout/Breakdown Levels: A breakout above the upper Bollinger Band ($327.91) could trigger a significant uptrend, while a breakdown below the lower Bollinger Band ($296.94) would indicate a more bearish scenario.
Time-Sensitive Catalysts: No imminent catalysts are apparent, but earnings data would be a significant event risk.
Risk Management: Consider setting stop-loss levels at $295.00 or implementing a position sizing strategy to manage risk.
Note: This report provides an objective analysis of the stock's technical and fundamental signals, as well as its market context and positioning. It does not provide buy or sell recommendations.
Generated
News
All COR news →
Specialty biologics now drive over half of U.S. pharmaceutical spending.
Showing 1–10 of 11
Page 1 of 2
Earnings History
12 of 16 under expected move
Avg Expected Move
5.30%
Avg Actual Move
4.44%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-04 | Pre-Market | 4.26% | 4.77% | 1.12x | Exceeded |
| 2021-05-05 | Pre-Market | 1.60% | 0.78% | 0.49x | Within |
| 2021-11-04 | Pre-Market | 4.94% | 0.63% | 0.13x | Within |
| 2023-11-02 | Pre-Market | 5.29% | 2.64% | 0.50x | Within |
| 2024-01-31 | Pre-Market | 3.99% | 5.51% | 1.38x | Exceeded |
| 2024-05-01 | Pre-Market | 4.56% | 4.12% | 0.90x | Within |
| 2024-07-31 | Pre-Market | 5.00% | 2.96% | 0.59x | Within |
| 2024-11-06 | Pre-Market | 5.11% | 4.87% | 0.95x | Within |
| 2025-02-05 | Pre-Market | 4.53% | 0.68% | 0.15x | Within |
| 2025-05-07 | Pre-Market | 4.81% | 4.74% | 0.99x | Within |
| 2025-08-06 | Pre-Market | 6.45% | 2.93% | 0.45x | Within |
| 2025-11-05 | Pre-Market | 6.23% | 2.75% | 0.44x | Within |
| 2026-02-04 | Pre-Market | 5.76% | 8.79% | 1.53x | Exceeded |
| 2026-05-06 | Pre-Market | 5.66% | 17.38% | 3.07x | Exceeded |
| 2026-08-05 | Pre-Market | 8.10% | 3.57% | 0.44x | Within |
| 2026-11-04 | Pre-Market | 8.52% | 3.96% | 0.46x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
COR Options Activity & IV Rank
COR IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 30.3%
7-DTE IV: 33.3%
Expected Move: $27.15
7-DTE Move: $17.80
Days to Exp: 42 (2026-12-18)
Options Flow
Call Volume: 476
Put Volume: 88
P/C Volume: 0.185
BULLISH
Call OI: 2,405
Put OI: 2,409
P/C OI: 1.002
Total OI: 4,814
ATM Options Pricing
ATM Call: $11.65
ATM Put: $15.50
Call %: 3.5%
Put %: 4.6%
Chain Summary
Chain Volume: 1,974
Chain OI: 17,173
Last Updated: 11/6/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
LOW γ vs HISTORY
Estimated net dealer gamma is at the 17th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
17%
vs own history
GEX tilt
+0.07
OI-weighted, today
Vanna tilt
+0.59
δ-sensitivity to IV
Charm tilt
-0.59
δ-decay vs time
Vanna tilt +0.59: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.59: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 49 ATM contracts, 10k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
100%
+42.0
pts
EXTREME
ATM 32.3% / Wing 74.4%
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)41.1MediumNov 6
IV Rank (30 DTE)41.0MediumNov 6
Straddle Price (30 DTE)$27.15Nov 6
Beta Analysis
Risk Metrics
Beta: 0.0162
Alpha: -1.91%
Correlation: 0.0070
R-Squared: 0.0%
Stock Volatility: 31.6%
Market Volatility: 13.6%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own COR
7 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $396.2M | #67 of 6285 | +74.6% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $339.5M | #51 of 3716 | +206.7% | 13F | |
| Point72 Hedge fund Steve Cohen | $193.5M | #67 of 1945 | +69.4% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $69.3M | #180 of 4729 | +12.9% | 13F | |
| Soros Fund Management Family office George Soros, Robert Soros, Jonathan Soros | $21.3M | #99 of 251 | new | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $9.6M | #342 of 997 | +139.3% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $6.7M | #1287 of 3138 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
COR Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 194,965,000 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
28 filers$366.39M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $85.77M | 23.41% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $68.62M | 18.73% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $37.30M | 10.18% | 2026-06-30 |
| 4 | Wolverine Trading, LLC Custodian | $30.44M | 8.31% | 2025-09-30 |
| 5 | Cubist Systematic Strategies, LLC | $27.82M | 7.59% | 2025-09-30 |
| 6 | Squarepoint Ops LLC | $22.84M | 6.23% | 2026-06-30 |
| 7 | Point72 Asset Management, L.P. | $16.41M | 4.48% | 2026-06-30 |
| 8 | Goldman Sachs Group Inc Custodian | $13.67M | 3.73% | 2026-06-30 |
| 9 | D. E. Shaw & Co., Inc. Custodian | $9.68M | 2.64% | 2026-06-30 |
| 10 | Delta Accumulation, LLC | $9.06M | 2.47% | 2026-06-30 |
| 11 | IMC-Chicago, LLC Custodian | $9.00M | 2.46% | 2026-06-30 |
| 12 | GROUP ONE TRADING LLC Custodian | $8.18M | 2.23% | 2026-06-30 |
| 13 | PFM Health Sciences, LP | $7.95M | 2.17% | 2026-06-30 |
| 14 | Millennium Management LLC Custodian | $5.57M | 1.52% | 2026-06-30 |
| 15 | Simplex Trading, LLC Custodian | $3.57M | 0.97% | 2026-06-30 |
| 16 | CAPSTONE INVESTMENT ADVISORS, LLC | $1.75M | 0.48% | 2026-06-30 |
| 17 | UBS Group AG Custodian | $1.64M | 0.45% | 2026-06-30 |
| 18 | BNP Paribas Financial Markets Custodian | $1.41M | 0.39% | 2026-06-30 |
| 19 | Qube Research & Technologies Ltd | $1.10M | 0.30% | 2026-06-30 |
| 20 | Walleye Trading LLC | $1.02M | 0.28% | 2026-06-30 |
| 21 | READYSTATE ASSET MANAGEMENT LP | $848.94K | 0.23% | 2026-06-30 |
| 22 | Walleye Capital LLC | $735.75K | 0.20% | 2026-06-30 |
| 23 | DV Trading LLC | $707.45K | 0.19% | 2026-06-30 |
| 24 | TUDOR INVESTMENT CORP ET AL | $452.77K | 0.12% | 2026-06-30 |
| 25 | Two Sigma Investments, LP Custodian | $367.87K | 0.10% | 2026-06-30 |
23 filers$119.99M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $28.35M | 23.63% | 2026-06-30 |
| 2 | Cubist Systematic Strategies, LLC | $23.72M | 19.77% | 2025-09-30 |
| 3 | Citadel Advisors LLC Custodian | $12.37M | 10.31% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $12.25M | 10.21% | 2026-06-30 |
| 5 | TUDOR INVESTMENT CORP ET AL | $9.56M | 7.97% | 2026-06-30 |
| 6 | Squarepoint Ops LLC | $7.70M | 6.41% | 2026-06-30 |
| 7 | BNP Paribas Financial Markets Custodian | $6.08M | 5.07% | 2026-06-30 |
| 8 | Wolverine Trading, LLC Custodian | $3.94M | 3.29% | 2025-09-30 |
| 9 | Point72 Asset Management, L.P. | $3.74M | 3.11% | 2026-06-30 |
| 10 | Millennium Management LLC Custodian | $3.48M | 2.90% | 2026-06-30 |
| 11 | IMC-Chicago, LLC Custodian | $3.11M | 2.59% | 2026-06-30 |
| 12 | CAPSTONE INVESTMENT ADVISORS, LLC | $1.41M | 1.18% | 2026-06-30 |
| 13 | Curi Capital, LLC | $848.94K | 0.71% | 2026-06-30 |
| 14 | Walleye Capital LLC | $792.34K | 0.66% | 2026-06-30 |
| 15 | Qube Research & Technologies Ltd | $764.05K | 0.64% | 2026-06-30 |
| 16 | READYSTATE ASSET MANAGEMENT LP | $509.36K | 0.42% | 2026-06-30 |
| 17 | Delta Accumulation, LLC | $481.07K | 0.40% | 2026-06-30 |
| 18 | Allianz Asset Management GmbH | $396.17K | 0.33% | 2026-06-30 |
| 19 | Two Sigma Investments, LP Custodian | $226.38K | 0.19% | 2026-06-30 |
| 20 | Simplex Trading, LLC Custodian | $141.49K | 0.12% | 2026-06-30 |
| 21 | HAP TRADING, LLC | $72.05K | 0.06% | 2025-09-30 |
| 22 | UBS Group AG Custodian | $28.30K | 0.02% | 2026-06-30 |
| 23 | Atwater Malick LLC | $6.87K | <0.01% | 2026-09-30 |
COR Insider Trading (Form 4)
Latest: 2026-11-03Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-11-03 | Lazarus Krikorian | SVP & Chief Accounting Officer | Sell (S) | −986 | $330.96 | -$326.3K | EDGAR |
| 2026-11-03 | Ellen Cooper | Director | Award (A) | +91 | $330.84 | $30.1K | EDGAR |
| 2026-11-03 | Lauren M Tyler | Director | Award (A) | +91 | $330.84 | $30.1K | EDGAR |
| 2026-11-03 | Pawan Verma | EVP, Chief Data & Info Officer | Mixed | +4,284 | $330.84 | -$1.41M | EDGAR |
| 2026-11-03 | Dennis M Nally | Director | Award (A) | +106 | $330.84 | $35.1K | EDGAR |
| 2026-10-05 | Lazarus Krikorian | SVP & Chief Accounting Officer | Sell (S) | −986 | $303.18 | -$298.9K | EDGAR |
| 2026-10-05 | Robert E Sanchez | Director | Award (A) | +275 | — | EDGAR | |
| 2026-09-17 | Lon R Greenberg | Director | Sell (S) | −1,280 | $321.30 | -$411.3K | EDGAR |
| 2026-09-02 | Lazarus Krikorian | SVP & Chief Accounting Officer | Sell (S) | −985 | $325.97 | -$321.1K | EDGAR |
| 2026-08-25 | Elizabeth S Campbell | Executive Vice President | Sell (S) | −11,300 | $324.12 | -$3.66M | EDGAR |
| 2026-08-04 | Dennis M Nally | Director | Award (A) | +113 | $311.34 | $35.2K | EDGAR |
| 2026-08-04 | Lauren M Tyler | Director | Award (A) | +97 | $311.34 | $30.2K | EDGAR |
| 2026-08-04 | Ellen Cooper | Director | Award (A) | +97 | $311.34 | $30.2K | EDGAR |
| 2026-07-07 | Elizabeth S Campbell | Executive Vice President | Award (A) | +49 | $240.53 | $12.0K | EDGAR |
| 2026-07-07 | Silvana Battaglia | Executive Vice President | Award (A) | +58 | $240.53 | $14.0K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
COR Insider Holdings
19 insiders · @ $336.06
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Walgreens Boots Alliance, Inc. | 10%+ Owner | 14,541,270 | $4.89B | -$314.53M | 1 | 2025-02-10 |
| 2 | Steven H Collis | Executive Chairman | 337,262 | $113.34M | -$105.70M | 29 | 2025-09-18 |
| 3 | James F Cleary | Chief Financial Officer | 160,357 | $53.89M | $0 | 16 | 2026-03-13 |
| 4 | Robert P. Mauch | President & CEO | 69,155 | $23.24M | -$37.51M | 27 | 2026-02-24 |
| 5 | Dermot Mark Durcan | Director | 31,767 | $10.68M | $2.27M | 6 | 2026-06-22 |
| 6 | Silvana Battaglia | Executive Vice President | 23,624 | $7.94M | -$6.63M | 22 | 2026-07-07 |
| 7 | Elizabeth S Campbell | Executive Vice President | 19,455 | $6.54M | -$9.22M | 21 | 2026-08-25 |
| 8 | Lon R Greenberg | Director | 17,128 | $5.76M | -$1.25M | 8 | 2026-09-17 |
| 9 | Lazarus Krikorian | SVP & Chief Accounting Officer | 14,197 | $4.77M | -$4.58M | 21 | 2026-11-03 |
| 10 | Pawan Verma | EVP, Chief Data & Info Officer | 13,686 | $4.60M | $0 | 4 | 2026-11-03 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
COR Board & Officers
As of SEC filings through Nov 3, 2026Directors 12
- Lon R Greenberg · since May 16, 2013
- Dermot Mark Durcan · since Sep 8, 2015
- Dennis M Nally · since Jan 1, 2020
- Lorence H. Kim · since Oct 1, 2022
- Redonda Miller · since Jan 1, 2023
- Lauren M Tyler · since Oct 1, 2023
- Werner Baumann · since Oct 1, 2023
- Frank Clyburn · since Oct 1, 2024
- Robert P. Mauch · listed since Nov 2024
- Lori Ryerkerk · since Jun 1, 2025
- Ellen Cooper · since Jan 20, 2026
- Robert E Sanchez · since Oct 1, 2026
Officers 6
- Robert P. Mauch · President & CEO · listed since Nov 2024
- Silvana Battaglia · Executive Vice President · since May 16, 2019
- Elizabeth S Campbell · Executive Vice President · since Sep 1, 2021
- Eva C Boratto · Chief Financial Officer · since Jun 29, 2026
- Lazarus Krikorian · SVP & Chief Accounting Officer · listed since Jun 2020
- Pawan Verma · EVP, Chief Data & Info Officer · since Oct 1, 2025
Changes in the last 10 years (29)
| Oct 1, 2026 | Robert E Sanchez became a director |
| Jun 29, 2026 | Eva C Boratto became Chief Financial Officer |
| Mar 17, 2026 | The company announced the departure of James F Cleary as Chief Financial Officer in an SEC filing |
| Jan 20, 2026 | Ellen Cooper became a director |
| Oct 1, 2025 | Pawan Verma became EVP, Chief Data & Info Officer |
| Aug 27, 2025 | The company announced the departure of Steven H Collis from the board in an SEC filing |
| Aug 27, 2025 | The company announced the departure of Steven H Collis as Executive Chairman in an SEC filing |
| Jun 1, 2025 | Lori Ryerkerk became a director |
| Jan 22, 2025 | The company announced the departure of Richard W Gochnauer from the board in an SEC filing |
| Jan 22, 2025 | The company announced the departure of Kathleen W Hyle from the board in an SEC filing |
| Nov 13, 2024 | Robert P. Mauch listed as President & CEO (previously Executive Vice President & COO) in SEC filings |
| Nov 13, 2024 | Robert P. Mauch first listed as a director in an SEC filing |
| Oct 23, 2024 | Steven H Collis listed as Executive Chairman (previously Chairman, President & CEO) in SEC filings |
| Oct 1, 2024 | Frank Clyburn became a director |
| Apr 30, 2024 | The company announced the departure of Gina Clark as Executive Vice President in an SEC filing |
| Oct 1, 2023 | Werner Baumann became a director |
| Oct 1, 2023 | Lauren M Tyler became a director |
| Jan 23, 2023 | The company announced the departure of Michael J Long from the board in an SEC filing |
| Jan 23, 2023 | The company announced the departure of Jane E Md Henney from the board in an SEC filing |
| Jan 1, 2023 | Redonda Miller became a director |
| Nov 4, 2022 | Robert P. Mauch listed as Executive Vice President & COO (previously Executive Vice President) in SEC filings |
| Oct 1, 2022 | Lorence H. Kim became a director |
| Sep 1, 2021 | Elizabeth S Campbell became Executive Vice President |
| Jun 9, 2020 | Lazarus Krikorian listed as SVP & Chief Accounting Officer (previously Senior Vice President) in SEC filings |
| Jan 1, 2020 | Dennis M Nally became a director |
| Aug 8, 2019 | Leslie E Donato became EVP & Chief Strategy Officer |
| May 16, 2019 | Silvana Battaglia became Executive Vice President |
| Mar 4, 2019 | Douglas R Conant reported in an SEC filing no longer being a director |
| Nov 16, 2018 | James F Cleary listed as Chief Financial Officer (previously Executive Vice President) in SEC filings |
Not reported recently (12)
- Walgreens Boots Alliance, Inc. · Last reported as a 10% owner in an SEC filing dated Feb 10, 2025
- Walgreens Boots Alliance Holdings LLC · Last reported as a 10% owner in an SEC filing dated Feb 10, 2025
- Leslie E Donato · Last reported as EVP & Chief Strategy Officer in an SEC filing dated Jul 5, 2024
- Ornella Barra · Last reported as a director in an SEC filing dated Mar 12, 2024
- Henry Wadsworth McGee III · Last reported as a director in an SEC filing dated Mar 13, 2023
- John G. Chou · Last reported as Executive Vice President in an SEC filing dated Dec 21, 2021
- Kathy H. Gaddes · Last reported as Executive Vice President in an SEC filing dated Feb 24, 2020
- Dale Danilewitz · Last reported as Executive Vice President in an SEC filing dated May 24, 2019
- Tim G. Guttman · Last reported as Chief Financial Officer in an SEC filing dated Nov 13, 2018
- Peyton R Howell · Last reported as Executive Vice President in an SEC filing dated Apr 5, 2018
- Sun Park · Last reported as Executive Vice President in an SEC filing dated Nov 20, 2017
- James Frary · Last reported as Executive Vice President in an SEC filing dated Nov 14, 2016
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
COR Proposed Insider Sales (Form 144)
Latest: 2026-09-16
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
6 filings
· $16.4M notice value
· 4 unique filers
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Cleary James F (2, $9.7M) · Campbell Elizabeth S (1, $3.7M) · Battaglia Silvana (2, $2.6M) · Lon Greenberg (1, $411K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-09-16 | Lon Greenberg | Director | 1,280 | $411.3K | 2026-09-16 | Merrill Lynch | — | EDGAR |
| 2026-09-11 | Battaglia Silvana | Former Officer | 1,324 | $430.3K | 2026-09-11 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-09-04 | Cleary James F | Former Officer | 10,000 | $3.35M | 2026-09-04 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-09-01 | Battaglia Silvana | Former Officer | 6,593 | $2.18M | 2026-09-01 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-08-24 | Campbell Elizabeth S | Officer | 11,301 | $3.66M | 2026-08-24 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-08-06 | Cleary James F | Officer | 20,000 | $6.33M | 2026-08-06 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2026-02-20 | Mauch Robert P. | Officer, Director | 3,762 | $1.35M | 2026-02-20 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-02-18 | Mauch Robert P. | Officer, Director | 1,333 | $479.2K | 2026-02-18 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-01-20 | Mauch Robert P. | Officer, Director | 5,096 | $1.81M | 2026-01-20 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2025-12-19 | Campbell Elizabeth S | Officer | 3,351 | $1.15M | 2025-12-19 | Fidelity Brokerage Services LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-05-29
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Accession | Link |
|---|---|---|
| 2026-05-29 | 0001104659-26-068357 | EDGAR |
| 2026-05-06 | 0001140859-26-000018 | EDGAR |
| 2026-03-23 | 0001104659-26-033022 | EDGAR |
| 2026-03-17 | 0001104659-26-029039 | EDGAR |
| 2026-03-06 | 0001140859-26-000014 | EDGAR |
| 2026-02-18 | 0001104659-26-016785 | EDGAR |
| 2026-02-13 | 0001104659-26-015272 | EDGAR |
| 2026-02-11 | 0001104659-26-013465 | EDGAR |
| 2026-02-10 | 0001140859-26-000012 | EDGAR |
| 2026-02-04 | 0001140859-26-000004 | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|---|---|
| 2025-11-25 | 0001140859-25-000131 | EDGAR |
| 2024-11-26 | 0001140859-24-000177 | EDGAR |
| 2023-11-21 | 0001140859-23-000197 | EDGAR |
| 2022-11-22 | 0001140859-22-000098 | EDGAR |
| 2021-11-23 | 0001140859-21-000058 | EDGAR |
| 2020-11-19 | 0001140859-20-000050 | EDGAR |
| 2019-11-19 | 0001140859-19-000040 | EDGAR |
| 2018-11-20 | 0001140859-18-000053 | EDGAR |
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-05-06 | 0001140859-26-000020 | EDGAR |
| 2026-02-04 | 0001140859-26-000006 | EDGAR |
| 2025-08-06 | 0001140859-25-000122 | EDGAR |
| 2025-05-07 | 0001140859-25-000083 | EDGAR |
| 2025-02-05 | 0001140859-25-000034 | EDGAR |
| 2024-07-31 | 0001140859-24-000119 | EDGAR |
| 2024-05-01 | 0001140859-24-000072 | EDGAR |
| 2024-01-31 | 0001140859-24-000019 | EDGAR |
| 2023-08-02 | 0001140859-23-000116 | EDGAR |
| 2023-05-02 | 0001140859-23-000084 | EDGAR |
ETF Holders
341 ETFs hold COR
25 shown · $10.76B total exposure · 0.17% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.07% | $1.7B | — | 2026-09-30 |
| 2 | VOO Vanguard S&P 500 ETF | Vanguard | 0.09% | $1.5B | — | 2026-09-30 |
| 3 | VO Vanguard Morningstar Mid-Cap ETF | Vanguard | 0.54% | $1.2B | — | 2026-09-30 |
| 4 | IVV iShares Core S&P 500 ETF | iShares (BlackRock) | 0.10% | $905.5M | $850.0B | 2026-11-04 |
| 5 | SPY State Street® SPDR® S&P 500® ETF Trust | SPDR (State Street) | 0.10% | $833.8M | $818.5B | 2026-11-04 |
| 6 | VTV Vanguard Morningstar Value ETF | Vanguard | 0.21% | $518.5M | — | 2026-09-30 |
| 7 | XLV State Street® Health Care Select Sector SPDR® ETF | SPDR (State Street) | 0.98% | $500.2M | $50.9B | 2026-11-04 |
| 8 | IWP iShares Russell Mid-Cap Growth ETF | iShares (BlackRock) | 2.03% | $372.2M | $18.3B | 2026-11-04 |
| 9 | VOE Vanguard Morningstar Mid-Cap Value ETF | Vanguard | 0.93% | $339.8M | — | 2026-09-30 |
| 10 | USMV iShares MSCI USA Min Vol Factor ETF | iShares (BlackRock) | 1.34% | $327.7M | $23.8B | 2026-11-04 |
| 11 | VIG Vanguard Dividend Appreciation ETF | Vanguard | 0.25% | $324.2M | — | 2026-09-30 |
| 12 | IWR iShares Russell Mid-Cap ETF | iShares (BlackRock) | 0.48% | $281.2M | $56.8B | 2026-11-04 |
| 13 | IWF iShares Russell 1000 Growth ETF | iShares (BlackRock) | 0.21% | $249.1M | $112.9B | 2026-11-04 |
| 14 | RSP Invesco S&P 500 Equal Weight ETF | Invesco | 0.21% | $218.4M | — | 2026-11-04 |
| 15 | SPYM State Street® SPDR® Portfolio S&P 500® ETF | SPDR (State Street) | 0.10% | $188.6M | $185.1B | 2026-11-04 |
| 16 | RWL Invesco S&P 500 Revenue ETF | Invesco | 1.76% | $186.9M | — | 2026-11-04 |
| 17 | VHT Vanguard Health Care ETF | Vanguard | 0.78% | $169.6M | — | 2026-09-30 |
| 18 | FTCS First Trust Capital Strength® ETF | First Trust | 1.95% | $159.2M | $8.2B | 2026-11-04 |
| 19 | TCAF T. Rowe Price Capital Appreciation Equity ETF | Nport | 2.00% | $148.0M | — | 2026-06-30 |
| 20 | DUHP Dimensional US High Profitability ETF | Dimensional | 0.74% | $145.3M | — | 2026-11-04 |
| 21 | IVE iShares S&P 500 Value ETF | iShares (BlackRock) | 0.22% | $113.0M | $51.7B | 2026-11-04 |
| 22 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.13% | $112.6M | — | 2026-11-04 |
| 23 | VONG Vanguard Russell 1000 Growth ETF | Vanguard | 0.16% | $91.6M | — | 2026-09-30 |
| 24 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.09% | $87.9M | $92.8B | 2026-11-04 |
| 25 | SPYV State Street® SPDR® Portfolio S&P 500® Value ETF | SPDR (State Street) | 0.22% | $85.9M | $39.3B | 2026-11-04 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
24.96
TTM Diluted EPS
$13.47
TTM Revenue
$332.77B
TTM Net Income
$2.62B
TTM Op. Cash Flow
$4.82B
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-06-30 | $84.75B | $763.52M | $3.94 | $2.65B |
| Q2 '26 | 2026-03-31 | $78.36B | $1.64B | $8.40 | $1.34B |
| Q1 '26 | 2025-12-31 | $85.93B | $559.65M | $2.87 | $-2.31B |
| Q4 '25 | 2025-09-30 | $83.73B | $-339.70M | $-1.74 | $3.13B |
| Q3 '25 | 2025-06-30 | $80.66B | $687.40M | $3.52 | $109.25M |
| Q2 '25 | 2025-03-31 | $75.45B | $717.87M | $3.68 | $3.35B |
| Q1 '25 | 2024-12-31 | $81.49B | $488.60M | $2.50 | $-2.72B |
| Q4 '24 | 2024-09-30 | $79.05B | $3.38M | $0.04 | $1.00B |
| Q3 '24 | 2024-06-30 | $74.24B | $483.46M | $2.42 | $2.48B |
| Q2 '24 | 2024-03-31 | $68.41B | $420.77M | $2.09 | $-878.44M |
| Q1 '24 | 2023-12-31 | $72.25B | $601.50M | $2.98 | $885.16M |
| Q4 '23 | 2023-09-30 | $68.92B | $350.56M | $1.73 | $1.83B |
Q3 2026 • period ending 2026-06-30 • filed 2026-08-05
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
24.96
P/B
20.24
P/S
0.20
EV/EBITDA
13.25
EV/Sales
0.22
ROE
81.0%
ROA
3.1%
Div Yield
0.69%
FCF Yield
7.35%
Debt/Equity
3.53
Current Ratio
—
Market Cap
$65.55B
as of 2026-11-06
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
3.93M
SI % of Float
2.15%
Days to Cover
3.43
Short Vol Ratio
43.6%
Free Float
182.72M
Float %
95.8%
Short interest 2026-10-15 • Short volume 2026-11-05 • Float 2026-08-13